 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] SK Bioscience announced on the 28th that its operating loss in the second quarter was 35.3 billion won based on consolidated financial statements. It turned into a deficit from 61.2 billion won in operating profit in the same period last year.
Sales reached 26.5 billion won during the same period. It increased by 28.6% compared to the first quarter, but decreased by 80.9% compared to the same period last year.
On a separate basis, cumulative operating losses in the first half rose to 64.5 billion won. This is also a deficit compared to 84.9 billion won in operating profit in the first half of last year. Cumulative sales in the first half recorded 47.1 billion won, down 79.1% from a year earlier.
Analysts say that the decrease in demand for the vaccine "Skycovione," which was concentrated during the COVID-19 pandemic, was affected by eased quarantine.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
